Clinical Trials Browser

Interventional × toripalimab × Breast × Clear all

NCT07602907 2026-05-22

Metronomic Oral Paclitaxel Monotherapy and Combined Immunotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose Exploration and Expansion Trial

Phase 2 Not yet recruiting

Advanced Breast Cancer

NCT06618014 2026-05-15

NeoTOP

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07378306 2026-04-21

FACT-TN

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07540533 2026-04-20

2025-370

Phase 2 Recruiting

Advanced Breast Cancer

NCT07457359 2026-03-09

NEOTRIO-2

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07410234 2026-02-13

Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07281976 2026-02-12

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms

NCT07383818 2026-02-03

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

Phase 2 Recruiting

Breast Neoplasms

NCT06682195 2026-01-14

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07111832 2025-12-18

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT06735131 2025-12-03

The Optimal Radioimmunotherapy Combinations for Advanced TNBC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07256964 2025-12-02

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07244874 2025-11-24

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06178159 2025-10-01

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07169994 2025-09-12

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06371274 2025-08-12

A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Phase NA Recruiting

Triple Negative Breast Neoplasms

NCT06611813 2025-08-12

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

Phase 2 Recruiting

Breast Neoplasms

NCT07101614 2025-08-03

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06914440 2025-07-15

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06977893 2025-05-18

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

Phase 3 Recruiting

Breast Neoplasms

NCT06964906 2025-05-11

NeoHunter

Phase 2 Recruiting

Breast Neoplasms

NCT06878625 2025-03-25

A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06642545 2025-02-17

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06105008 2024-08-23

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT06387628 2024-08-02

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06389006 2024-05-23

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT04418154 2024-05-21

NeoTENNIS

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT05955105 2024-05-21

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Phase 1/2 Recruiting

BreastDermatologicGynecologicHead & NeckSarcomaThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05749575 2023-03-01

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Phase 2 Unknown

Breast Neoplasms

NCT05491694 2022-08-08

HIFU

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05291910 2022-03-23

Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer

Phase 4 Unknown

Breast Neoplasms

NCT04389073 2022-02-25

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

Phase 2 Unknown

Breast Neoplasms

NCT05103917 2021-11-02

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Phase 1/2 Unknown

Triple Negative Breast Neoplasms